Articles with public access mandates - Rakesh K JainLearn more
OverallNIHDoDEuropean CommissionSusan G. KomenDFGGatesFWFHHMINSFSNSFWellcomeA*StarMRCChildren's Tumor Foundation, USACancer Research UKDOEFWOINSERMFCTRCNKWFEMBLSCLPancreatic Cancer Action Network, USAV Foundation, USANational Research Foundation, SingaporeCPRITLeducq Foundation, USAAmerican Brain Tumor AssociationCCSFRQSNSFCVolkswagen FoundationDNRFAcademy of FinlandCSIRDBTResearch Council of LithuaniaKnut and Alice Wallenberg FoundationVersus Arthritis, UKBBSRCBHFBreast Cancer Now, UKEPSRCWorldwide Cancer Research, UKYorkshire Cancer Research, UKState of CalifoniaGovernment of SpainNKFIAXA Research Fund, FranceHFSPOICRBELSPO
Not available anywhere: 7
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
P Carmeliet, RK Jain
Nature reviews Drug discovery 10 (6), 417-427, 2011
Mandates: US National Institutes of Health, Research Foundation (Flanders)
Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
RK Jain
Nature Reviews Cancer 8 (4), 309-316, 2008
Mandates: US National Institutes of Health
Using tumour phylogenetics to identify the roots of metastasis in humans
K Naxerova, RK Jain
Nature reviews Clinical oncology 12 (5), 258-272, 2015
Mandates: US National Institutes of Health
Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas
ER Gerstner, AG Sorensen, RK Jain, TT Batchelor
Current opinion in neurology 21 (6), 728-735, 2008
Mandates: US National Institutes of Health
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?
DG Duda, M Ancukiewicz, RK Jain
Journal of Clinical Oncology 28 (2), 183-185, 2010
Mandates: US National Institutes of Health
Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab
VA Levin, J Chan, M Datta, JL Yee, RK Jain
Journal of neuro-oncology 134, 325-330, 2017
Mandates: US National Institutes of Health
Transparent window models and intravital microscopy: imaging gene expression, physiological function and therapeutic effects in tumors
RK Jain, LL Munn, D Fukumura
Tumor models in cancer research, 641-679, 2011
Mandates: US National Institutes of Health
Available somewhere: 274
Molecular mechanisms and clinical applications of angiogenesis
P Carmeliet, RK Jain
Nature 473 (7347), 298-307, 2011
Mandates: US National Institutes of Health, Research Foundation (Flanders)
Understanding the tumor immune microenvironment (TIME) for effective therapy
M Binnewies, EW Roberts, K Kersten, V Chan, DF Fearon, M Merad, ...
Nature medicine 24 (5), 541-550, 2018
Mandates: US National Institutes of Health
Delivering nanomedicine to solid tumors
RK Jain, T Stylianopoulos
Nature reviews Clinical oncology 7 (11), 653-664, 2010
Mandates: US National Institutes of Health
A framework for advancing our understanding of cancer-associated fibroblasts
E Sahai, I Astsaturov, E Cukierman, DG DeNardo, M Egeblad, RM Evans, ...
Nature Reviews Cancer 20 (3), 174-186, 2020
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
Mandates: US National Institutes of Health, Fonds de recherche du Québec - Santé
Normalization of the vasculature for treatment of cancer and other diseases
S Goel, DG Duda, L Xu, LL Munn, Y Boucher, D Fukumura, RK Jain
Physiological reviews 91 (3), 1071-1121, 2011
Mandates: US National Institutes of Health
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology
U Prabhakar, H Maeda, RK Jain, EM Sevick-Muraca, W Zamboni, ...
Cancer research 73 (8), 2412-2417, 2013
Mandates: US National Institutes of Health
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
D Fukumura, J Kloepper, Z Amoozgar, DG Duda, RK Jain
Nature reviews Clinical oncology 15 (5), 325-340, 2018
Mandates: Bill & Melinda Gates Foundation, US National Institutes of Health, German …
Compact high-quality CdSe–CdS core–shell nanocrystals with narrow emission linewidths and suppressed blinking
O Chen, J Zhao, VP Chauhan, J Cui, C Wong, DK Harris, H Wei, HS Han, ...
Nature materials 12 (5), 445-451, 2013
Mandates: US National Institutes of Health
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia
RK Jain
Cancer cell 26 (5), 605-622, 2014
Mandates: US National Institutes of Health
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
CD Arvanitis, GB Ferraro, RK Jain
Nature Reviews Cancer 20 (1), 26-41, 2020
Mandates: US National Science Foundation, US National Institutes of Health, Susan G. Komen
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers
RK Jain
Journal of Clinical Oncology 31 (17), 2205-2218, 2013
Mandates: US National Institutes of Health
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
VP Chauhan, T Stylianopoulos, JD Martin, Z Popović, O Chen, ...
Nano-Enabled Medical Applications, 279-311, 2020
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program